Clopidogrel Resistance: Current Issues

Clopidogrel Resistance: Current Issues

Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complications. Dual antiplatelet therapy, combining aspirin and clopidogrel, is the standard care for patients having acute coronary syndromes or undergoing percutaneous coronary intervention according to the cu...

Full description

Bibliographic Details
Main Author: NS Neki
Format: Article
Language:English
Published: Enam Medical College, Dhaka 2016-05-01
Series:Journal of Enam Medical College
Subjects:
Part of the JOL Project Supported by INASP Bangladesh Journals OnLine (BanglaJOL) is a service to provide access to Bangladesh published research
and increase worldwide knowledge of indigenous scholarship. Read more. Browse By Issue By Author By Title Other Journals Login Username Password Remember me Journal Content Search Search Scope Browse By Issue By Author By Title Other Journals Subjects About The Author NS Neki Professor
Department of Medicine
Government Medical College
Amritsar
India and Visiting Professor
Institute of Cardiovascular Sciences
University of Minnitoba
Winnipeg
Canada India Article Tools Print this article Indexing metadata How to cite item Finding References Email this article (Login required) Email the author (Login required) Information For Readers For Authors Home > Journal of Enam Medical College > Vol 6
No 1 (2016) > Neki Clopidogrel Resistance: Current Issues NS Neki Abstract Antiplatelet agents are mainly used in the prevention and management of atherothrombotic complications. Dual antiplatelet therapy
combining aspirin and clopidogrel
is the standard care for patients having acute coronary syndromes or undergoing percutaneous coronary intervention according to the current ACC/AHA and ESC guidelines. But in spite of administration of dual antiplatelet therapy
some patients develop recurrent cardiovascular ischemic events especially stent thrombosis which is a serious clinical problem. Antiplatelet response to clopidogrel varies widely among patients based on ex vivo platelet function measurements. Clopidogrel is an effective inhibitor of platelet activation and aggregation due to its selective and irreversible blockade of the P2Y12 receptor. Patients who display little attenuation of platelet reactivity with clopidogrel therapy are labeled as low or nonresponders or clopidogrel resistant. The mechanism of clopidogrel resistance remains incompletely defined but there are certain clinical
cellular and genetic factors including polymorphisms responsible for therapeutic failure. Currently there is no standardized or widely accepted definition of clopidogrel resistance. The future may soon be realised in the routine measurement of platelet activity in the same way that blood pressure
cholesterol and blood sugar are followed to help guide the therapy
thus improving the care for millions of people. This review focuses on the methods used to identify patients with clopidogrel resistance
the underlying mechanisms
metabolism
Acute coronary syndrome; Percutaneous coronary intervention; Clopidogrel; Platelet aggregation
Online Access:http://www.banglajol.info/index.php/JEMC/article/view/26381

Internet

http://www.banglajol.info/index.php/JEMC/article/view/26381

Similar Items